Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790593 | 0.80 | GLA (0.43) | CYP19A1HRH3 | |
| SCHEMBL9157917 | 0.77 | HPGD (0.40) | CYP2A6ALDH1A1KCNH2IDO1 | |
| SCHEMBL6781894 | 0.76 | SMN1; SMN2 (0.46) | ALDH1A1KCNH2IDO1 | |
| SCHEMBL1350580 | 0.75 | DNM1 (0.44) | KCNH2 | |
| SCHEMBL3753968 | 0.75 | HSD17B10 (0.76) | CYP2A6TSHRHSD17B10LOXL2CYP19A1 | |
| SCHEMBL1453582 | 0.74 | TSHR (0.46) | CYP2A6TSHRHSD17B10LOXL2CYP19A1 | |
| SCHEMBL20915394 | 0.74 | CA2 (0.46) | — | |
| SCHEMBL10568033 | 0.73 | HSD17B10 (0.79) | CYP2A6TSHRHSD17B10LOXL2CYP19A1 | |
| SCHEMBL2997975 | 0.73 | HSD17B10 (0.86) | CYP2A6TSHRHSD17B10LOXL2CYP19A1 | |
| SCHEMBL10567414 | 0.73 | HSD17B10 (0.86) | CYP2A6TSHRHSD17B10LOXL2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | disclosed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PRKCB, PRKCA, PRKCG | CYP2A6 3310/4885TSHR 3713/4885HSD17B10 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.